Literature DB >> 9833983

Antibodies as carrier proteins.

B N Rehlaender1, M J Cho.   

Abstract

Pre-existing antibodies against a drug substance can significantly alter the pharmacokinetic profile of the drug in the circulation. Rapid clearance, mediated by complement or Fc receptors, occurs for crosslinked immune complexes, but not for complexes containing only one or two antibodies. With antibodies functioning as carrier proteins, monovalent antigens may enjoy a prolonged circulatory half-life, as observed in the case of digoxin, insulin, and various interleukins. While such an effect should be highly sensitive to fluctuations in antibody affinity and titer, it may present a means of extending the circulation of potent but rapidly cleared therapeutic agents. This mini-review attempts to delineate the causal relation between the factors influencing antibody binding and the circulatory life of a therapeutic agent, be it a small drug or a macromolecule.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9833983     DOI: 10.1023/a:1011936007457

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  32 in total

Review 1.  Complement and immune complexes.

Authors:  M J Walport; K A Davies
Journal:  Res Immunol       Date:  1996-02

Review 2.  Humanized antibodies.

Authors:  G Winter; W J Harris
Journal:  Trends Pharmacol Sci       Date:  1993-05       Impact factor: 14.819

3.  Properties of soluble immune complexes.

Authors:  R W Lightfoot; R E Drusin; C L Christian
Journal:  J Immunol       Date:  1970-12       Impact factor: 5.422

4.  Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats.

Authors:  J L Valentine; S M Owens
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

Review 5.  Mechanism and computer simulation of immune complex formation, opsonization, and clearance.

Authors:  M Head; N Meryhew; O Runquist
Journal:  J Lab Clin Med       Date:  1996-07

6.  Enhancement of the biologic effects of interleukin-3 in vivo by anti-interleukin-3 antibodies.

Authors:  A T Jones; H J Ziltener
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

7.  Increased circulating interleukin-6 (IL-6) activity in endotoxin-challenged mice pretreated with anti-IL-6 antibody is due to IL-6 accumulated in antigen-antibody complexes.

Authors:  E Martens; C Dillen; W Put; H Heremans; J van Damme; A Billiau
Journal:  Eur J Immunol       Date:  1993-08       Impact factor: 5.532

8.  An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2.

Authors:  L P Courtney; J L Phelps; L M Karavodin
Journal:  Immunopharmacology       Date:  1994 Nov-Dec

9.  Splenic uptake of immune complexes in man is complement-dependent.

Authors:  K A Davies; K Erlendsson; H L Beynon; A M Peters; K Steinsson; H Valdimarsson; M J Walport
Journal:  J Immunol       Date:  1993-10-01       Impact factor: 5.422

10.  Pharmacokinetic alteration in rats of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2.

Authors:  J Sato; N Hamaguchi; K Doken; S Iwasa; Y Ogawa; H Toguchi
Journal:  Biol Pharm Bull       Date:  1994-04       Impact factor: 2.233

View more
  15 in total

1.  Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

Authors:  Christoph Rader; Subhash C Sinha; Mikhail Popkov; Richard A Lerner; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

Review 2.  Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy.

Authors:  Narendra Chirmule; Vibha Jawa; Bernd Meibohm
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

Review 3.  Clinical pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Ron J Keizer; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

Review 4.  Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.

Authors:  Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-15       Impact factor: 2.745

Review 5.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

6.  Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics.

Authors:  Lei Zhou; Sarah A Hoofring; Yu Wu; Thuy Vu; Peiming Ma; Steven J Swanson; Narendra Chirmule; Marta Starcevic
Journal:  AAPS J       Date:  2012-10-09       Impact factor: 4.009

7.  The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics.

Authors:  Siva Charan Devanaboyina; Sandra M Lynch; Raimund J Ober; Sripad Ram; Dongyoung Kim; Alberto Puig-Canto; Shannon Breen; Srinath Kasturirangan; Susan Fowler; Li Peng; Haihong Zhong; Lutz Jermutus; Herren Wu; Carl Webster; E Sally Ward; Changshou Gao
Journal:  MAbs       Date:  2013 Nov-Dec       Impact factor: 5.857

8.  Anti-drug antibodies as drug carriers. I. For small molecules.

Authors:  B N Rehlaender; M J Cho
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

9.  Antibodies as drug carriers III: design of oligonucleotides with enhanced binding affinity for immunoglobulin G.

Authors:  Enzo Palma; David G Klapper; M J Cho
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

Review 10.  Targeting FcRn for the modulation of antibody dynamics.

Authors:  E Sally Ward; Siva Charan Devanaboyina; Raimund J Ober
Journal:  Mol Immunol       Date:  2015-03-09       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.